Abstract
The use of live, recombinant virus for immunisation against influenza produced a number of respiratory illnesses, some severe, in patients with chronic obstructive airways disease. These patients are probably more susceptible to the influenza virus than are normal subjects. Special care will be needed in testing these viruses on patients with respiratory disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beare A. S., Hobson D., Reed S. E., Tyrrell D. A. A comparison of live and killed influenza-virus vaccines. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines. Lancet. 1968 Aug 24;2(7565):418–422. doi: 10.1016/s0140-6736(68)90463-7. [DOI] [PubMed] [Google Scholar]
- Beare A. S., Schild G. C., Craig J. W. Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses. Lancet. 1975 Oct 18;2(7938):729–732. doi: 10.1016/s0140-6736(75)90720-5. [DOI] [PubMed] [Google Scholar]
- Morris C. A., Freestone D. S., Stealey V. M., Oliver P. R. Recombinant WRL 105 strain live attenuated influenza vaccine. Immunogenicity, reactivity, and transmissibility. Lancet. 1975 Aug 2;2(7927):196–199. doi: 10.1016/s0140-6736(75)90670-4. [DOI] [PubMed] [Google Scholar]